Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.60 |
| ▸ | CA2 | P00918 | 1/20 | 0.60 |
| ▸ | GLS | O94925 | 3/20 | 0.42 |
| ▸ | LCK | P06239 | 6/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.38 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17397826 | 0.87 | CA1 (0.51) | CA1CA2GLSLCKALDH1A1 | |
| SCHEMBL10404148 | 0.82 | KDM4E (0.53) | CA1CA2GLSALDH1A1GAA | |
| SCHEMBL15386264 | 0.81 | CA1 (0.61) | CA1CA2LCKALDH1A1RECQL | |
| SCHEMBL18834722 | 0.81 | CA1 (0.61) | CA1CA2GLSLCKALDH1A1 | |
| SCHEMBL283195 | 0.80 | CA1 (0.60) | CA1CA2ALDH1A1KDM4EHPGD | |
| SCHEMBL15861545 | 0.79 | CA1 (0.58) | CA1CA2GLSLCKALDH1A1 | |
| SCHEMBL8834429 | 0.79 | ALDH1A1 (0.63) | CA1CA2GLSALDH1A1GAA | |
| SCHEMBL31421146 | 0.78 | CA1 (0.57) | CA1CA2GLSALDH1A1GAA | |
| SCHEMBL1691097 | 0.75 | CA1 (0.55) | CA1CA2GLSLCKALDH1A1 | |
| SCHEMBL31377111 | 0.75 | CA1 (0.55) | CA1CA2GLSALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827629-B2 | CDGSH iron sulfur domain 2 activators and use thereof | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2023-11-28 | — | — | US | disclosed |
| US-11827629-B2 | CDGSH iron sulfur domain 2 activators and use thereof | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2023-11-28 | — | — | US | disclosed |
| US-20220411418-A1 | CDGSH IRON SULFUR DOMAIN 2 ACTIVATORS AND USE THEREOF | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2022-12-29 | — | — | US | disclosed |
| WO-2022251343-A2 | CDGSH IRON SULFUR DOMAIN 2 ACTIVATORS AND USE THEREOF | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2022-12-01 | — | — | WO | disclosed |
| US-7871982-B2 | Lincomycin derivatives and antimicrobial agents comprising the same as active ingredient | MEIJI SEIKA KAISHA, LTD. (JP) | 2011-01-18 | — | — | US | disclosed |
| US-20090156512-A1 | potent activity against resistant pneumococci | MEIJI SEIKA KAISHA, LTD. (JP) | 2009-06-18 | — | — | US | disclosed |
| EP-1970377-A1 | LINCOMYCIN DERIVATIVE AND ANTIBACTERIAL AGENT CONTAINING THE SAME AS ACTIVE INGREDIENT | MEIJI SEIKA KAISHA LTD. (JP) | 2008-09-17 | — | — | EP | disclosed |
| US-4307116-A | BACTERICIDES | RHONE-POULENC INDUSTRIES (FR) | 1981-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411418-A1 | CDGSH IRON SULFUR DOMAIN 2 ACTIVATORS AND USE THEREOF | CISD2, CISD1, FECH | CA1 4388/4885CA2 3302/4885GLS 175/4885 |
| US-20090156512-A1 | potent activity against resistant pneumococci | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NAT1, NPM1 | CA1 4451/4885CA2 3115/4885GLS 1709/4885 |
| US-11827629-B2 | CDGSH iron sulfur domain 2 activators and use thereof | CISD2, CISD1, FECH | CA1 4388/4885CA2 3302/4885GLS 175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.